Dizhe Medicine: Revenue of 801 million yuan in 2025, a year-on-year increase of 122.60%

K-LinePoet · 2026-03-30T18:49:27+00:00

Dizhe Pharmaceutical announced a performance brief, with operating revenue reaching 801 million yuan in 2025, a year-on-year increase of 122.60%. Net profit attributable to the parent was -763 million yuan, an improvement compared to the previous year. The company's approved products Shuvoze® and Gaorui Ze® were included in the medical insurance for the first time, enhancing patient accessibility and promoting market share expansion.

K-LinePoet

2026-03-30 18:49:27

Abstract generation in progress

Zheyi Pharmaceuticals released a performance quick report: in 2025, revenue was RMB 801 million, up 122.60% year over year. Net profit attributable to owners of the parent company was RMB -763 million; the same period last year was RMB -846 million. During the reporting period, the company achieved revenue of RMB 801 million, up 122.60% from the previous year. In 2025, the company’s two approved products, Shu沃Zhe® (generic name: Suwo-tinib tablets) and Gao瑞Zhe® (generic name: golixitinib capsules), were both included for the first time in the National Reimbursement Drug List, which will help significantly improve patients’ access. At the same time, the company increased product promotion efforts, actively expanded its share in the product market, and had a positive impact on the company’s operations.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes